Inebilizumab, an anti-CD19 monoclonal antibody, reduced attacks, disability progression, hospitalisations, and new lesions in NMOSD compared with placebo in the randomised controlled period of the N-MOmentum pivotal study [1]. The drug was well-tolerated, with adverse event (AE) rates similar to placebo. A total of 230 patients were randomised to inebilizumab (n=174) or placebo (n=56) monotherapy for 6.5 months. Of those, 91% were aquaporin 4-IgG seropositive (AQP4-IgG+). Study recruitment was stopped early because of clear evidence of efficacy. Inebilizumab reduced the risk of attacks by 72.8% (P<0.001). This percentage was even higher in the AQP4-IgG+ population: 77.3% (P<0.001). During the randomised controlled period, 87.9% of participants did not have a single attack. The most common AEs included urinary tract infections and infusion-related reactions, without any difference between groups.
Additional analyses of the SAkuraSky study revealed that satralizumab, an IL-6R inhibitor, significantly reduced relapse risk, especially in AQP4-IgG+ patients [2]. The 83 participating NMOSD patients had been randomly assigned to receive satralizumab 120 mg or placebo at week 0, 2, and 4 and every 4 weeks thereafter, added to stable immunosuppressant treatment. Satralizumab significantly reduced risk of protocol-defined relapse by 62% vs placebo (P=0.0184). Relapse risk was reduced by 79% with satralizumab in AQP4-IgG+patients (n=55). The proportion of relapse-free patients at weeks 48 and 96 were 91.5% and 91.5% with satralizumab, and 59.9% and 53.3% with placebo, respectively. In AQP4-IgG- patients, relapse risk was reduced by 34% vs placebo. In the overall study population, annualised relapse risk was 0.11 in the satralizumab group and 0.32 in the placebo group.
- Cree B, et al. EAN 2019, O4122.
- Yamamura T, et al. EAN 2019, O4113.
Posted on
Previous Article
« Statin use elevates risk of eczema and atopic dermatitis Next Article
Motor nerve biopsy for early diagnosis of lower motor neuron syndromes »
« Statin use elevates risk of eczema and atopic dermatitis Next Article
Motor nerve biopsy for early diagnosis of lower motor neuron syndromes »
Table of Contents: EAN 2019
Featured articles
Letter from the Editor
Alzheimer’s Disease and other Dementias
A necessary shift of focus to the earlier stages of Alzheimer’s
Antipsychotics increase mortality regardless of comorbidity
Epilepsy
Neuroinflammatory pathways as biomarkers and treatment targets
Long-term effect of recurrent febrile seizures
Migraine
The role of neurogenic inflammation in migraine
Multiple Sclerosis
Treating MS from disease onset
Randomised and observational studies comparing treatments
Autologous haematopoietic stem cell transplantation
Neuromuscular Disorders
Parkinson's Disease and other Movement Disorders
Inflammation may change the course of Parkinson’s disease
Opicapone: follow-up on the BIPARK I and II trials
Epigallocatechin gallate does not modify MSA progression
Stroke
Thrombo-inflammation during ischaemia/reperfusion
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy